Study to Evaluate the Safety and Efficacy of Ublituximab in Participants With Schizophrenia
← catalyst calendarNCT07680946 · readout in 835 d
Sponsored by TG Therapeutics, Inc. (industry) · TGTX — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
60estimated
Sites
2
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-07-03 | actual | When the study began enrolling |
| Primary completion | 2028-12-01 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-03-01 | estimated | The whole study's end, after follow-up |
| First posted | 2026-07-02 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-21 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Schizophrenia
Intervention
- Drug: Ublituximab — also filed as BRIUMVI, TG-1101
Primary outcome
what the primary-completion date above is the date OFPercentage of Participants with at Least 20% Reduction From Baseline in PANSS Total Score
measured At Week 12
Permalink · TGTX's whole pipeline · Catalyst calendar · Every registered study · What changed